title: Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.
abstract: The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.
authors.affiliation: Novartis Vaccines and Diagnostics, Cambridge, MA, USA. christopher.gill@novartis.com
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Gill
authors.forename: Roger
authors.initials: R
authors.lastname: Baxter
authors.forename: Alessandra
authors.initials: A
authors.lastname: Anemona
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ciavarro
authors.forename: Peter
authors.initials: P
authors.lastname: Dull
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood*; D001770:Blood Bactericidal Activity; D005260:Female; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination / Q000379:methods*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate